Consultation on the Prescription Drug List: Fluticasone propionate

Notice to the reader:

The online consultation is now closed.

The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for Adrenocortical Hormones or their salts or derivatives on the Human Prescription Drug List (PDL) to permit the non-prescription use of Fluticasone propionate for the conditions listed. Only the human part of the PDL is proposed to be revised.

A question-and-answer document has also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.

How to Get Involved

This consultation is open for comment until February 10, 2016. Please read through the information provided in the link below titled "Consultation Document".  Once read, please submit your comments via email, facsimile or by mail to:

Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9

Telephone: 613-957-1058
Facsimile: 613-941-1812
e-mail: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca

Interested parties are encouraged to provide comments and suggestions by February 10, 2016.

Reporting to Canadians

The results of the consultation will be made available on this website.

If you have any questions, contact us the Prescription Drug Status Committee.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.

Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: